RE: X thread24 Nov 2023 19:47
Fourth, funding. There are three aspects to this point: (i) Blencowe has already obtained a $5m technical assistance grant from the DFC, affiliated with the US Government. This is funding a large part of the DFS costs. 15/n
(ii) The deal with the DFC is that they get first refusal to provide/introduce whole project funding. Thus, that relationship is likely to lead to a complete funding solution. The company is already in discussions about this. 16/n
(iii) Short term funding. It is widely perceived that Blencowe needs to raise some money, on top of the DFC money. In a recent interview, the CEO expressed great (tempting to say complete) confidence that this is going to come from institutional investment. 17/n
He also said he expects never to do a retail placing again. And he indicated that news on this topic is very close. If and when high quality funding is announced, that should in my view have a very reassuring effect on the market. 18/n
Fifth, share price. A couple of spikes and dips aside, BRES has been trading between 4p and 6p all year. For most of the last six months it has been between 4.6p and 5.7p. It is currently around 5.05p. 19/n
The notable thing about this is that in the last few months we have seen (a) the DFC grant, (b) the successful bulk testing, and (c) the successful SPG work, yet the share price hasn’t budged. 20/n
When a company keeps on delivering great news and the share price doesn’t move, the effect is like a coiling spring. When it snaps, there is a long way to move up to reach fair value. In my view, it’s only a matter of time with #BRES. 21/end